THERAPY DOSSIER · th-8a9063dbd8de

Polyclonal antibodies raised against divalent type b flagellin plus PilA

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Burn
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27836582 ↗2016Reported benefit

Antibodies raised against divalent type b flagellin and pilin provide effective immunotherapy against Pseudomonas aeruginosa infection of mice with burn wounds.

MouseBurnUnspecifiedBALB/cmaleProphylactic administration, therapeutic administration, and a combined prophyl…

Model: Burn wound with Pseudomonas aeruginosa infection

Antibodies against flagellin b plus PilA showed synergistic improvement of opsonophagocytosis and reduction of cell invasion compared with monovalent antibodies. Prophylactic and combined prophylactic plus therapeutic regimens improved survival of mice infected with disparate Pseudomonas aeruginosa…

Extraction: extract · Supplied extraction confidence: 0.62. Machine-extracted fields require source verification.

Loading the evidence…